Further US delay for GSK's Cervarix
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinesaid it would wait to include final data from its pivotal Phase III trial of cervical cancer vaccine Cervarix in its US filing, which it hopes will eventually strengthen its label even if it further delays a decision from theFDA.